Protalix BioTherapeutics reported third quarter 2026 results that significantly outperformed analyst expectations, driven by higher goods sales to commercial partner Chiesi. The company remains debt-free and maintains a cash position of $48.5 million to support its clinical pipeline.
Key Highlights
- Total revenue of $21.9 million exceeded the $12.4 million estimate, reflecting a 23.5% year-over-year increase in goods sales primarily to partner Chiesi.
- Management reaffirmed full-year 2026 revenue guidance of $78 million to $83 million, noting that year-to-date revenues of $75.6 million already approach the lower end of the target.
- The Phase 2 RELEASE study for PRX-115 in uncontrolled gout remains on schedule, with top-line results anticipated in the second half of 2027.